PALIPERIDONE ER: A NEW TREATMENT FOR SCHIZOPHRENIA
Abstract: A new
second-generation antipsychotic for the treatment of schizophrenia has been
found. Paliperidone ER (Invega ™) was approved in 2007 by Food and Drug Administration
(FDA) to treat patients with schizophrenia. The formulation of Paliperidone ER
by using the Alza OROS (Osmotic-controlled Release Oral-delivery System) and
utilizing osmotic pressure release medication in smooth blood plasma levels. Several
studies that were sponsored by Johnson and Johnson Pharmaceutical Research and
Development found that all doses of paliperidone ER is effective in controlling
a broad range of the symptoms of schizophrenia and personal and social
functioning and generally well tolerated.
Author: Dahlia
Kode Jurnal: jpkedokterangg130246
